ARUP LABORATORIES | aruplab.com
500 Chipeta Way, Salt Lake City, Utah 84108-1221
phone: 801-583-2787, toll free: 800-522-2787
Tracy I. George, MD, Chief Medical Officer

Patient Report

Patient Age/Gender: Unknown

Specimen Collected: 09-Dec-20 13:44

X-CBFB-MYH11 inv(16) Detection, Quant | **Received: 09-Dec-20 13:44** | **Report/Verified: 09-Dec-20 13:49**

	Result	Units	Reference Interval
CBFB-MYH11 Source	Whole Blood		
CBFB-MYH11 Result	Detected [f1 i1]		
CBFB-MYH11/ABL1 Ratio	1.00000		

Result Footnote

f1: CBFB-MYH11 Result

CBFB-MYH11 fusion transcripts (type A) were detected by RT-qPCR. This indicates the presence of inv(16)/t(16;16) positive cells in the sample.

This result has been reviewed and approved by Kristin Karner, M.D.

Test Information

i1: CBFB-MYH11 Result

INTERPRETIVE INFORMATION: CBFB-MYH11 inv(16) Quantitative

This test is designed to detect and quantify CBFB-MYH11 fusion transcripts (type A, D or E) which result from inv(16)/t(16;16);CBFB-MYH11, a recurrent genetic abnormality found in a subset of patients with acute myeloid leukemia.

Methodology:
Patient RNA is isolated, reverse transcribed into cDNA, and amplified using primers specific for the CBFB and MYH11 genes. A normalized ratio is calculated representing CBFB-MYH11 transcripts / ABL1 transcripts.

Limitations:
Translocations involving other genes or gene partners will not be detected.
The limit of quantitation for this test is 0.0001 (NCN).

Results of this test must always be interpreted within the patient's clinical context and in conjunction with other relevant data. Results should not be used alone for a diagnosis of malignancy.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing Lab